Endogenous opioid peptide responses to opioid and anti-inflammatory medications following eccentric exercise-induced muscle damage.
To determine the effects of Vicoprofen, Ibuprofen, and a placebo on the responses of endogenous opioid peptides following eccentric exercise-induced muscle damage 36 healthy men (age: 22.8 years; height: 178.8+/-6.2cm; body mass: 78.9+/-13.7kg; body fat: 15.8+/-6.5%) volunteered to participate in the study. Each participant was evaluated for pain 24h post and randomly assigned to an experimental group: VIC (Vicoprofen), IBU (Ibuprofen), or P (placebo). Medication was given four times daily (i.e., VIC (hydrocodone bitartrate 7.5mg with Ibuprofen 200mg) and IBU 200mg). Blood was obtained at rest and at 0, 24, 48, 72, 96 and 120h following the eccentric exercise damage protocol. No significant changes for B-END were observed in the resting values over the recovery period among any of the treatment conditions. Conversely for plasma P-F, VIC and IBU had significantly (P<0.05) higher plasma concentrations of P-F above placebo at 24, 48, 72, and 96 and 120h with VIC higher than IBU and placebo conditions at 48, 72, 96, and 120h. Significant resting elevations were observed for P-F from pre-exercise at 48, 72, 96, and 120h for VIC; at 72 and 96h for IBU and no changes in the placebo treatment. Less tissue damage (MRI analyses), improved physical function as well as reduced pain was observed for the VIC condition over IBU and placebo. These data indicate that exogenous medications appear to be differentially stimulating the peripheral (adrenal medulla) opioid neuroendocrine responses as measured by plasma concentrations.
Kraemer
William J
WJ
Human Performance Laboratory, Department of Kinesiology, University of Connecticut, Storrs, CT 06269-1110, USA. William.Kraemer@uconn.edu
Joseph
Michael F
MF
Volek
Jeff S
JS
Hoffman
Jay R
JR
Ratamess
Nicholas A
NA
Newton
Robert U
RU
Fragala
Maren S
MS
French
Duncan N
DN
Rubin
Martyn A
MA
Scheett
Timothy P
TP
McGuigan
Michael R
MR
Thomas
Gwendolyn A
GA
Gomez
Ana L
AL
Häkkinen
Keijo
K
Maresh
Carl M
CM
D000293:Adolescent; D000328:Adult; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D015444:Exercise; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D018482:Muscle, Skeletal / Q000473:pathology / Q000503:physiopathology; D018847:Opioid Peptides / Q000378:metabolism*; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology; D010147:Pain Measurement; D005082:Physical Exertion; D010919:Placebos / Q000627:therapeutic use; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D018847:Opioid Peptides; D010919:Placebos